SPECIAL COMMENTARIES: Edited by Steven G. DeeksLong-acting injectable HIV therapies: the next frontier: RepublicationThornhill, Johna,b; Orkin, Chloea,bAuthor Information aDepartment of Infection & Immunity, The Royal London Hospital, Bart Health NHS Trust bDepartment of Immunobiology, The Blizard Institute, Queen Mary University of London, London, United Kingdom Correspondence to John Thornhill, Department of Infection & Immunity, The Royal London Hospital, Bart Health NHS Trust, London, United Kingdom. E-mail: [email protected] This article was previously published in Current Opinion in Infectious Diseases. Curr Opin Infect Dis. 2021 Feb 1;34(1):8–15. doi: 10.1097/QCO.0000000000000701 Current Opinion in HIV and AIDS: March 2021 - Volume 16 - Issue 2 - p 98-105 doi: 10.1097/COH.0000000000000670 Buy Metrics Abstract Purpose of review There has been significant development of long-acting injectable therapy for the management of HIV in recent years that has the potential to revolutionise HIV care as we know it. This review summarises the data and outlines the potential challenges in the field of long-acting antiretroviral therapy (ART). Recent findings In recent years, monthly and two monthly long-acting injectable ART in the form of cabotegravir and rilpivirine has shown safety and efficacy in large-scale phase 3 randomised control trials. Also, agents with novel mechanisms of action, such as Lenacapavir, have been tested in early-phase studies and are currently being tested in phase 2-3 clinical trials; if successful, this may allow six-monthly dosing schedules. Summary However, despite evidence that suggests that these therapies are efficacious and acceptable to patients, the challenge of integrating these agents into our current healthcare infrastructure and making these novel agents cost-effective and available to the populations most likely to benefit remains. The next frontier for long-acting therapy will be to introduce these agents in a real-world setting ensuring that the groups most in need of long-acting therapy are not left behind. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.